A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device

Inclusion Criteria: * Age 25-55 years with regular menses and at least one symptom related to uterine fibroids (for example heavy bleeding). * Completed child-bearing. * At least one uterine fibroid of 3 cm diameter or greater with a prevailing pathology (e.g. as opposed to adenomyosis) of fibroids determined through abdominal/transvaginal ultrasound. * Confirmation of the ability to clearly visualise bilateral uterine arteries with 2/3DPD. * Dominant fibroid (defined as \>3cm in diameter) must be well vascularised as determined by CE-MRI (for Group 2 and 3 patients only). * Able to tolerate the required prolonged supine position during treatment (approximately 6 hours). * Cervix suitable for tenaculum placement as determined by pelvic exam. * Normal Pap smear within the last 36 months. * Agrees to participate in the study, and following review of the patient information sheet documents this agreement by signing the Ethics Committee approved informed consent. Exclusion Criteria: * Prior endometrial ablation, uterine artery embolization, or uterine artery ligation. * Pregnancy (As confirmed by a urine pregnancy test at screening and immediately prior to procedure). * One or more lower uterine segment fibroids determined through pelvic exam which in the examiner's opinion would prevent proper clamp application. * Any known contraindications to the contrast agent to be used for the CE-MRI as determined by the study radiologist (for Group 2 and 3 patients only). * Pelvic mass outside the uterus suggesting other disease processes. * An intrauterine device (IUD) in place during the day of procedure. * Hydronephrosis as determined by interpretation of a pre-procedure renal ultrasound. * No ureteral jets observed on ultrasound prior to clamping. * Presence of a pedunculated fibroid determined by ultrasound, hysteroscopy, or saline infused sonography or CE MRI. * Any current acute or chronic systemic infection or localized pelvic infection, including an unresolved urinary tract infection. * Clinical history of any thromboembolic disease. * History of gynecologic malignancy, atypical endometrial hyperplasia, or pelvic inflammatory disease. * Using anticoagulation therapy (except OTC treatments, e.g. aspirin), or has a known underlying bleeding disorder. * In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.